Blog
Talacotuzumab Biosimilar: Advancing CD123-Targeted Cancer Therapy
Talacotuzumab, a humanized monoclonal antibody targeting CD123, has shown promise in treating acute myeloid leukemia (AML) and other hematologic malignancies. As a key immunotherapy, it e
…
27th Nov 2024
Vorsetuzumab Biosimilar: Advancing CD70-Targeted Immunotherapy
Vorsetuzumab, a monoclonal antibody targeting CD70, is an investigational therapy designed to treat hematologic malignancies and solid tumors. CD70, a member of the tumor necrosis factor
…
27th Nov 2024
Pembrolizumab Biosimilar: Expanding Access to PD-1 Immunotherapy
Pembrolizumab (Keytruda), a monoclonal antibody targeting programmed death-1 (PD-1), has revolutionized cancer treatment by enhancing the immune system's ability to detect and destroy can
…
27th Nov 2024
Daratumumab Biosimilar: Advancing CD38-Targeted Therapy
Daratumumab, a human monoclonal antibody targeting CD38, is a breakthrough therapy for multiple myeloma (MM) and other CD38-expressing hematologic malignancies. It enhances immune-mediate
…
26th Nov 2024
Elotuzumab Biosimilar: A New Frontier in Multiple Myeloma Treatment
Elotuzumab is a monoclonal antibody that targets SLAMF7 (signaling lymphocytic activation molecule F7), a protein highly expressed on multiple myeloma (MM) cells and natural killer (NK) c
…
26th Nov 2024
Atezolizumab Biosimilar : Enhancing Access to PD-L1 Immunotherapy
Atezolizumab (Tecentriq) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), a key immune checkpoint used by cancer cells to evade immune detection. By inhibiting PD-L1,
…
25th Nov 2024
Cobolimab Biosimilar: Expanding Access to TIM-3 Immune Checkpoint Inhibition
Cobolimab is an investigational monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), an immune checkpoint receptor implicated in T-cell exhaustion an
…
25th Nov 2024
Immunoglobulins: Structure, Function, and Clinical Importance
Immunoglobulins (Igs), also known as antibodies, are glycoproteins produced by B cells and plasma cells. They play a central role in the immune system by identifying and neutralizing path
…
20th Nov 2024
Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies
Phosphorothioate is a chemical modification commonly used in oligonucleotide-based therapies to enhance the stability and efficacy of therapeutic nucleic acids. In this modification, one
…
15th Nov 2024
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC
Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch
…
14th Nov 2024
M2 Supplement for Organoid Cell Culture: Enhancing Growth and Differentiation
The use of M2 Supplement in organoid culture has revolutionized the way researchers cultivate and maintain these three-dimensional (3D) cellular models. Organoids—self-organizing cell clu
…
12th Nov 2024
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer
Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
…
12th Nov 2024
Renal Cell Carcinoma: Understanding, Diagnosing, and Treating Kidney Cancer
Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, originating in the lining of the proximal renal tubules. RCC accounts for approximately 90% of all kidney cancers and
…
12th Nov 2024
Typical Workflow of CRISPR-Cas9 Genome Editing
The CRISPR-Cas9 system is a powerful tool for genome editing, enabling precise modifications to DNA. The typical CRISPR-Cas9 workflow involves several steps, from designing guide RNAs to
…
6th Nov 2024
TREM2: Exploring Its Role in Tumor-Associated Macrophages and Cancer Immunotherapy
Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophages
…
31st Oct 2024
Dual PD-1/PD-L2 Blockade: Expanding the Horizons of Cancer Immunotherapy
Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi
…
29th Oct 2024
TNFRSF9: Enhancing Immune Cell Activity Against Tumors
Introduction to TNFRSF9 and Its Role in Immune ActivationTNFRSF9, also known as 4-1BB or CD137, is a co-stimulatory receptor expressed on the surface of T cells, natural killer (NK) cells
…
29th Oct 2024
CD155: Breaking Immune Suppression in Tumor Environments
Introduction to CD155 in Cancer ImmunotherapyCD155, also known as Poliovirus Receptor (PVR), is a transmembrane protein that plays a pivotal role in tumor immune evasion. While CD155 is n
…
29th Oct 2024
CD39: A Novel Target to Overcome Immunosuppression in Cancer
Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within t
…
21st Oct 2024
CD73: Combating Tumor Immunosuppression by Targeting Adenosine
Introduction to CD73 and Tumor Immunosuppression CD73, also known as ecto-5'-nucleotidase, is an enzyme found on the surface of various cells, including tumor cells and immune cells.
…
21st Oct 2024
BTLA: A Key Player in Immune Regulation and Cancer Therapy
Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressi
…
16th Oct 2024
ICOS: Stimulating the Immune System for Superior Cancer Therapy
Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
…
14th Oct 2024
B7-H4: A New Frontier in Immune Checkpoint Inhibition
The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
…
14th Oct 2024
LILT: A Novel Immune Checkpoint for Cancer Therapy
Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr
…
14th Oct 2024